IBDoc® Faecal calprotectin self-test retrospective audit in a District General Hospital (DGH)
Avery et al.
Calprotectin Home Testing – What do the patients think?
Amanda Appleton, Alpha Laboratories Ltd
New faecal calprotectin cut-off points for remission and active disease defined by UCEIS and Nancy indices in ulcerative colitis (UC)
Walsh et al.
Clinical performance of four fecal calprotectin assays from smartphone-based home test to high throughput central lab methods
Reinhard et al.
Point-of-care faecal calprotectin testing in patients with paediatric inflammatory bowel disease during the COVID-19 pandemic
Jere et al.
Compliance with Faecal calprotectin home testing as standard during COVID-19 pandemic compared to laboratory based testing pre-COVID
Edwards et al.
Rapid Calprotectin POC: Quantum Blue®
A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn’s disease
Lobatón et al.
Rapid fecal calprotectin test for prediction of mucosal inflammation in ulcerative colitis and Crohn disease: a prospective cohort study
Moniuszko et al.
Rapid Therapeutic Drug Monitoring: Quantum Blue®
Patient-near Infliximab trough-level testing by a novel quantitative rapid test: The Quantum Blue Infliximab test
Lindsjø et al.
Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays
Afonso J et al.
Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassays
Afonso J et al.
First successful comparison of Quantum Blue® rapid TDM assay standardization with WHO international standard for infliximab
Keller et al.
Pharmacist-led proactive therapeutic drug monitoring with infliximab (PROXIMO): utility of and cost-saving with the use of a rapid assay for assessing drug level
C Rentsch et al.
General Literature
Videos
An Introduction to IBDoc® Calprotectin Home Testing

















